In Vivo Analysis of the State of the Human Upa Enhancer Following Stimulation by TPA
Oncogene (1999) 18, 2836 ± 2845 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $12.00 http://www.stockton-press.co.uk/onc In vivo analysis of the state of the human uPA enhancer following stimulation by TPA Ine s IbanÄ ez-Tallon1,3, Giuseppina Caretti1,2, Francesco Blasi1,2 and Massimo P Crippa*,1 1Laboratory of Molecular Genetics, DIBIT - Ospedale. S. Raaele, Via Olgettina 58, 20132 Milano, Italy; 2Department of Genetics and Microbial Biology, University of Milano, Via Celoria 20, 20133 Milano, Italy We have analysed in vivo the 72.0 kb enhancer of the upstream combined PEA3/AP-1A and a downstream human urokinase-type plasminogen activator (uPA) gene AP-1B site (Berthelsen et al., 1996; De Cesare et al., in HepG2 cells, in which gene expression can be induced 1995; Nerlov et al., 1992). The AP-1 sites are separated by phorbol esters. The results reveal that, within the by a 74 bp `cooperation mediator' (COM) region, regulatory region, the enhancer, the silencer and the which contains the binding sites for several proteins, minimal promoter become hypersensitive to deoxyribo- named urokinase enhancer factors (UEF; Berthelsen et nuclease I (DNase I) upon induction of transcription. al., 1996; De Cesare et al., 1996; Nerlov et al., 1992). In The hypersensitivity of the enhancer can be reversed HeLa cells, the NF-kB site at 71865, downstream of after removal of the inducer. In vivo footprinting analysis AP-1B and in A549 cells the site at 71592 have also indicates that all the cis-acting elements of the enhancer, been reported to play a role in phorbol esters induction previously identi®ed in vitro, are occupied in vivo upon of uPA gene expression (Guerrini et al., 1996; Novak 12-O-tetradecanoyl-phorbol-13-acetate (TPA) stimula- et al., 1991).
[Show full text]